Abstract:The human epidermal growth factor receptor (Her) family plays an important role in cell survival and proliferation, and is implicated in oncogenesis. Overexpression of Her2/neu is associated with aggressive disease and poor prognosis. Herceptin, the only anti-Her2/neu, humanized monoclonal antibody approved by FDA for therapy of mammary carcinoma is currently and successfully prescribed for treatment of Her2/neu positive cancer. However, in 40-60% of all patients with Her2/neu-overexpressing tumors, Herceptin has little or no effect. The goal of this study was to demonstrate the construction and characterization of various Herceptin-based immunotoxins, loaded with a highly cytotoxic recombinant gelonin (rGel) molecule. Utilizing a humanized anti-Her2/neu scFv (4D5), we generated 2 orientation constructs: 4D5/rGel and rGel/4D5. We also generated a conventional chemical conjugate with full-length Herceptin (Herceptin/rGel conjugate), and we generated a unique fusion of anti-Her2/neu IgG containing 2 rGel molecules (Aglyco-Herceptin/rGel). This is the first report of the preparation of active full-length antibody-toxin construct from E.coli. In vitro studies showed that all immunotoxins retained the affinity and specificity of the original antibody, as well as the biological activity of rGel toxin. Against the Her2/neu overexpressing cancer cell lines, all immunotoxins demonstrated specific cytotoxic effects, even against Herceptin-resistant breast cancer cells. Against ovarian (SKOV3) cells, the Herceptin/rGel conjugate, Aglyco-Herceptin/rGel and rGel/4D5 fusion constructs demonstrated the best in vitro efficacy (IC 50 of 0.28nM, 12.19nM and 1.57nM for each construct respectively vs 70.86 nM for 4D5/rGel). rGel/4D5 outperformed 4D5/rGel demonstrating improved internalization efficiency and increased intracellular delivery of rGel. All the immunotoxins displayed similar minimal exposure times to target cells for optimal cytotoxic activity. All constructs demonstrated a distinct cell-killing efficiency time course. Functional stability studies of the constructs showed that all remained biologically active after incubation in human plasma. Efficacy studies of the various constructs against SKOV3 tumor xenografts are ongoing and will be reported. Based on our in vitro results, the bivalent full-length antibody-toxin immunotoxins were superior to the corresponding recombinant monovalent constructs. Among monovalent constructs, the rGel/4D5 fusion was superior in vitro overall to 4D5/rGel. Different orientations of antibody and toxin can promote optimal cell internalization and toxicity of the immunotoxin, and may be valuable considerations for further construct optimization. Research conducted, in part, by the Clayton Foundation for Research. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1759. doi:10.1158/1538-7445.AM2011-1759

Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency

High Level Expression and Characterization of the Recombinant Immunotoxin DAB389-4D5 Scfv Targeting HER2/neu-positive Ovarian Carcinoma Cells

HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis

Manufacture and Evaluation of a HER2-positive Breast Cancer Immunotoxin 4D5fv-Pe25

Design Optimization and Characterization of Her2/neu-targeted Immunotoxins: Comparative in Vitro and in Vivo Efficacy Studies

Design Optimization And Characterization Of Novel Herceptin-Based Immunotoxins For Cancer Therapy. Enhanced Antitumor Activity In Vitro And In Vivo

Design, Expression, Purification and Characterization of the Recombinant Immunotoxin 4D5 Scfv-Trail

Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells

HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity

HER2-specific Immunotoxins Constructed Based on Single-Domain Antibodies and the Improved Toxin PE24X7.

Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain

Single-chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity.

A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity

A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells

A Targeted Immunotherapy Approach for HER2/neu Transformed Tumors by Coupling an Engineered Effector Domain with Interferon-Γ

PE38KDEL-loaded Anti-Her2 Nanoparticles Inhibit Breast Tumor Progression with Reduced Toxicity and Immunogenicity

A Bispecific Immunotoxin (IHPP) with a Long Half-Life Targeting HER2 and PDGFRβ Exhibited Improved Efficacy Against HER2-positive Tumors in a Mouse Xenograft Model.

Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides

Abstract 2730: Anti-Her2/neu Immunotoxins: Impact of Monovalent and Bivalent Designs on in Vitro and in Vivo Antitumor Efficacy

Construction and Characterization of the Recombinant Immunotoxin RTA-4D5-KDEL Targeting HER2/neu-positive Cancer Cells and Locating the Endoplasmic Reticulum.

Design, Synthesis and Bioactivity Evaluation of Novel Fusion Peptides and Their CPT Conjugates Inducing Effective Anti-Tumor Responses on HER2 Positive Tumors